Revenue: As of FY2025 Q4, the actual value is USD 666 K.

EPS: As of FY2025 Q4, the actual value is USD -2.21.

EBIT: As of FY2025 Q4, the actual value is USD -1.127 M.

Financial Highlights

Cash and Cash Equivalents

• As of December 31, 2025, cash and cash equivalents totaled $3,505 thousand, compared to $3,137 thousand as of December 31, 2024.

Net Cash Used in Operating Activities

• Net cash used in operating activities was -$4.8 million for the twelve months ended December 31, 2025, compared to -$8.0 million for the same period of 2024.

Segment Revenue

• Product Revenue - Fire Safety:
  • For the three months ended December 31, 2025, product revenue from fire safety sales and distribution was $666 thousand, up from $0 for the same period in 2024.
  • For the twelve months ended December 31, 2025, product revenue from fire safety sales and distribution was $747 thousand, up from $0 for the same period in 2024.
• Clinical Trial Supply Revenue:
  • For the twelve months ended December 31, 2024, clinical trial supply revenue was $43 thousand, with no revenue from this segment in 2025.

Operating Costs

• Cost of Sales:
  • For the three months ended December 31, 2025, cost of sales related to fire safety equipment was $545 thousand, up from $0 for the same period in 2024.
  • For the twelve months ended December 31, 2025, cost of sales related to fire safety equipment was $609 thousand, up from $0 for the same period in 2024.
• Research and Development (R&D) Expenses:
  • For the three months ended December 31, 2025, R&D expenses were -$47 thousand, significantly lower than $880 thousand for the same period in 2024.
  • For the twelve months ended December 31, 2025, R&D expenses were $848 thousand, a substantial decrease from $6,655 thousand for the same period in 2024.
  • R&D expenses for fadraciclib were $0 for the three months ended December 31, 2025, and $0.4 million for the year, compared to $0.8 million and $5.0 million respectively in 2024, due to the liquidation of the UK subsidiary.
  • R&D expenses for plogosertib were $0 for the three months ended December 31, 2025, and $0.4 million for the year, compared to $0.1 million and $1.6 million respectively in 2024, prior to its sale in October 2025.
• General and Administrative (G&A) Expenses:
  • For the three months ended December 31, 2025, G&A expenses were $1,250 thousand, up from $946 thousand for the same period in 2024, primarily due to one-time costs associated with changes of control.
  • For the twelve months ended December 31, 2025, G&A expenses were $7,717 thousand, up from $5,392 thousand for the same period in 2024, primarily due to one-time costs associated with changes of control.

Operating Loss

• Operating loss for the three months ended December 31, 2025, was -$1,082 thousand, an improvement from -$1,826 thousand for the same period in 2024.
• Operating loss for the twelve months ended December 31, 2025, was -$8,427 thousand, an improvement from -$12,004 thousand for the same period in 2024.

Other Income, Net

• Total other income, net, for the three months ended December 31, 2025, was $476 thousand, compared to an expense of -$30 thousand for the same period in 2024.
• Total other income, net, for the twelve months ended December 31, 2025, was $5,436 thousand, a significant increase from $10 thousand for the same period in 2024.
• This increase for the year was primarily driven by a $4,947 thousand gain on deconsolidation of a former subsidiary and a $300 thousand receipt from the sale of the plogosertib asset in October 2025.

Net Loss

• Net loss for the three months ended December 31, 2025, was -$611 thousand (including stock-based compensation expense of $700 thousand), compared to -$3,050 thousand (including stock-based compensation expense of $100 thousand) for the same period in 2024.
• Net loss for the twelve months ended December 31, 2025, was -$2,998 thousand (including stock-based compensation expense of $2,300 thousand), a substantial improvement from -$11,212 thousand (including stock-based compensation expense of $600 thousand) for the same period in 2024.

Balance Sheet Highlights

• Total Current Assets: Increased to $6,256 thousand as of December 31, 2025, from $3,674 thousand as of December 31, 2024.
• Total Assets: Increased to $8,185 thousand as of December 31, 2025, from $4,094 thousand as of December 31, 2024.
• Total Current Liabilities: Decreased to $1,332 thousand as of December 31, 2025, from $6,268 thousand as of December 31, 2024.
• Stockholders’ Equity: Improved to $6,842 thousand as of December 31, 2025, from -$2,174 thousand as of December 31, 2024.

Outlook / Guidance

Bio Green Med Solution, Inc. estimates that its current cash resources will fund planned expenditure into the third quarter of 2026. The report also includes a general forward-looking statements disclaimer, noting that actual results may differ materially due to various risks and uncertainties, which are more fully described in the Company’s other SEC filings. No specific future outlook or guidance for financial performance is provided within the Form 8-K document itself beyond the cash runway estimate.